查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1535303

真实世界证据解决方案市场规模、份额、预测、趋势分析：按组件、按应用、按最终用户 - 到 2031 年的全球预测

Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 254 Pages | 订单完成后即时交付

价格

2023 年全球现实世界证据 (RWE) 解决方案市场规模为 26.2 亿美元。该市场预计将从 2024 年的 29.4 亿美元增至 2031 年的 63.7 亿美元，2024-2031 年预测期间复合年增长率为 11.7%。

该报告基于全面的一手和二手研究以及对市场情景的深入分析，提供了该行业的关键驱动因素、限制因素、挑战和机遇。该市场的推动因素包括慢性病的增加、药物开发的延迟以及相关的开发成本的增加、对个人化医疗保健的日益关注、向基于价值的医学的转变以及药物开发和商业化，其中包括扩大真实药物的采用。例如，IQVIA 于 2024 年 6 月宣布推出 One Home for Sites。此数位平台可作为临床试验场所进行临床试验所需的所有关键系统和任务的仪表板。

此外，新兴国家和对端到端 RWE 服务的日益关注正在为现实世界的解决方案市场创造巨大的成长机会。然而，市场扩张可能会因不愿依赖实地研究和缺乏数据收集品质控製而受到限制。此外，缺乏开发 RWE 的标准化方法以及对资料隐私和安全的担忧给在该市场运营的公司带来了重大挑战。

按组件划分，资料集细分市场预计将在 2024 年占据 RWE 解决方案市场的最大份额。 RWE 资料集源自于与现实世界中不同人群的患者结果相关的各种来源。该解决方案提供了有关未满足的需求以及对患者和医疗保健系统的财务和临床影响的深刻资讯。此外，它基于更大的数据集、更低的成本和更有效的临床试验管理。

从应用来看，市场准入和报销/覆盖决策部分预计将在 2024 年占据 RWE 解决方案市场的最大份额。 RWE 的市场准入解决方案利用预测分析和数据驱动的洞察力，对医疗产品的有效性和价值进行全面评估，支持基于价值的定价策略，并推动带来有利的报销结果。庞大的市场份额是由医疗保健成本上升、监管机构对RWE 的接受度提高、承保决策中临床价值证据的重要性日益增加以及常规临床环境和异质患者群体中治疗效果的补充数据的可用性推动的。

在最终用户中，製药、生物技术和医疗器材公司领域预计将在 2024 年占据 RWE 解决方案市场的最大份额。收集即时临床后药物数据、监测药物反应、扩大 RWE 的使用以证明临床试验之外新疗法的价值、加快药物测试和延长批准时间等几个变量占了很大份额。

对全球 RWE 解决方案市场区域状况的详细分析提供了五个主要区域（北美、欧洲、亚太地区、中东和非洲以及拉丁美洲）的详细定性和定量见解。涵盖各地区主要国家。

到 2024 年，北美预计将占据全球 RWE 解决方案市场的最大份额，其次是欧洲、亚太地区、拉丁美洲以及中东和非洲。北美的显着份额是由慢性病发病率上升、更严格的药物审批指南、21世纪的治疗方法、电子数据集的广泛使用、强大的医疗保健行业以及医疗保健中大数据的使用推动的。包括扩大

调查范围:

真实世界证据解决方案市场评估：按组成部分

  • 资料集
    • 个别资料集
  • EMR/EHR/临床资料
  • 申请资料
  • 药局资料
  • 产品/疾病登记资料
  • 基因资料
  • 其他的个别资料集
    • 整合资料集
  • 咨询服务

注意：其他单独的资料集包括从行动装置、穿戴式装置和社群媒体产生的资料。

真实世界证据解决方案市场评估：按应用划分

  • 市场进入和偿付/适用范围的决策
  • 医药品开发·核准
    • 肿瘤学
    • 神经学
    • 免疫学
    • 心血管疾病
    • 其他的治疗领域
  • 上市后监测
  • 医疗设备的开发与核准
  • 其他的用途

註1：其他治疗领域包括传染病、肌肉骨骼疾病、皮肤病、呼吸系统疾病。

註 2：其他用途包括监管和临床决策。

真实世界证据解决方案市场评估：按最终用户

  • 製药，生物科技，医疗设备企业
  • 医疗保健付款者
  • 医疗保健供应商
  • 其他的终端用户

註：其他最终使用者包括学术研究机构、病患权益团体、监管机构和健康科技评估机构。

真实世界证据解决方案市场评估：按地区

  • 北美
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 瑞士
  • 比利时
  • 其他欧洲(RoE)
  • 亚太地区(APAC)
  • 中国
  • 日本
  • 印度
  • 韩国
  • 台湾
  • 新加坡
  • 澳洲
  • 其他亚太地区(RoAPAC)
  • 南美
  • 巴西
  • 墨西哥
  • 其他南美国家(RoLATAM)
  • 中东·非洲

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场洞察

  • 概要
  • 市场成长的要素
    • 市场动态
      • 促进因素
        • 越来越重视个人化医疗保健
        • 药物开发的延迟以及相关的开发成本增加
        • 慢性疾病增加
        • 转向以价值为基础的医疗保健
        • 医疗保健领域大数据的激增
      • 阻碍因素
        • 不愿意进行实际的临床试验
      • 机会
        • 新兴国家
        • 日益关注端到端 RWE 服务
      • 课题
        • 缺乏 RWE 开发的标准化研究方法
    • 要素分析
  • 主要市场趋势
    • RWE产业上人工智慧的引进
      • 人工智慧技术在以下领域的应用不断成长：
        • 临床试验设计
        • 患者丰富和招募的建模和预测
        • 临床试验医疗机构的选择
        • 病患监测与管理、药物顺从性和保留率
        • 使用人工智慧进行临床试验分析
        • 透过策略伙伴关係和协作外包人工智慧解决方案
        • 利用人工智慧解决方案进入市场
        • 使用人工智慧解决方案进行上市后监控
    • 在药物开发和商业化中越来越多地采用 RWE
    • 企业整合增加
    • 利用真实世界证据改善病患治疗效果并创造价值
  • 基于人工智慧的 RWE 解决方案案例研究
    • 基于人工智慧的 RWE 解决方案，用于医疗器材上市后监控 - Huma.AI（美国）
    • 基于人工智慧的 RWE 解决方案支援药物研发的临床决策 - Owkin, Inc.
    • 用于市场准入的人工智慧整合 RWE 解决方案 - Medaffcon Oy（芬兰）
    • 利用人工智慧和机器学习演算法获得真实数据洞察 - Aetion, Inc.（美国）和 Quinten Health（法国）
    • 由人工智慧驱动的 RWE 平台用于追踪不良事件 - Data2Life（以色列）
    • 利用 AI 支援的 RWE 解决方案预测重症监护病房病患的健康状况 - PHASTAR（英国）
  • 法规分析
    • 概要
    • 北美
    • 欧洲
    • 亚太地区
    • 全球其他地区
  • 价格设定模式(EMR/基因/整合资料集)
    • 摘要
    • 按病患记录付费（按数量定价）
    • 按使用量付费（基于价值的定价）
    • 年度订阅

第5章 真实世界证据解决方案市场评估:各零件

  • 概要
  • 资料集
    • 不同的资料集
      • EMR/EHR/临床资料
      • 申请资料
      • 药局资料
      • 产品/疾病登记资料
      • 基因资料
      • 其他的个别资料集
    • 整合资料集
  • 咨询与分析

第6章 真实世界证据解决方案市场评估:各用途

  • 概要
  • 市场进入和偿付/适用范围的决策
  • 医药品开发·核准
    • 癌症领域
    • 神经学
    • 免疫学
    • 心血管疾病
    • 其他的治疗领域
  • 上市后监测
  • 医疗设备开发·核准
  • 其他的用途

第7章 真实世界证据解决方案市场评估:各终端用户

  • 概要
  • 製药，生物科技，医疗设备企业
  • 医疗保健payer
  • 医疗保健供应商
  • 其他的终端用户

第8章 真实世界证据解决方案市场评估:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞士
    • 比利时
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 台湾
    • 新加坡
    • 其他亚太地区
  • 南美
    • 巴西
    • 墨西哥
    • 其他南美国家
  • 中东·非洲

第9章 竞争情形

  • 简介
  • 主要成长策略
  • 竞争基准
  • 竞争仪表板
    • 产业领导者
    • 市场差异化要素
    • 领先企业
    • 新兴企业
  • 市场占有率分析
    • IQVIA Holdings Inc.(U.S.)
    • Icon plc(IRELAND)
    • Thermo Fisher Scientific Inc.(U.S.)

第10章 企业简介

  • IQVIA Holdings, Inc.
  • Icon plc
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Oracle Corporation
  • Elevance Health, Inc.
  • Clinigen Group Plc
  • Cognizant Technology Solutions Corporation
  • Revvity, Inc.
  • SAS Institute Inc.
  • Parexel International Corporation
  • Healthverity, Inc.

第11章 附录

Product Code: MRHC - 104253

Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User-Global Forecast to 2031

The global RWE solutions market was valued at $2.62 billion in 2023. This market is expected to reach $6.37 billion by 2031 from an estimated $2.94 billion in 2024, at a CAGR of 11.7% during the forecast period of 2024-2031.

Following a comprehensive primary & secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by the growing incidence of chronic diseases, delays in drug development and the consequent increase in development costs, the rising focus on personalized healthcare, a shift toward value-based care, and the growing adoption of real-world evidence solutions in drug development & commercialization. For instance, IQVIA introduced One Home for Sites in June 2024. This digital platform serves as a dashboard for all the essential systems and tasks needed by a clinical research site to conduct clinical trials.

Furthermore, emerging economies and a rising focus on end-to-end RWE services provide significant growth opportunities for the real-world solutions market. However, the market's expansion may be constrained by the unwillingness to rely on real-world research and the absence of quality control in data collection. Additionally, the lack of standardized methodologies for developing RWE and data privacy and security concerns pose a major challenge for the players operating in this market.

Among components, in 2024, the datasets segment is expected to account for the largest share of the RWE solutions market. RWE datasets originate from a range of sources related to patient outcomes in diverse populations in real-world contexts. With regard to unfulfilled needs and the financial and clinical effects on patients and healthcare systems, this solution offers insightful information. Additionally, it bases results on far larger data sets, lower expenses, and more effective clinical trial management.

Among applications, in 2024, the market access & reimbursement/coverage decisions segment is expected to account for the largest share of the RWE solutions market. Using predictive analysis and data-driven insights, RWE solutions for market access enable a comprehensive assessment of a medical product's efficacy and value, which can support value-based pricing strategies and result in favorable reimbursement outcomes. The significant market share is ascribed to several factors, including escalating healthcare expenses, growing regulatory body acceptance of RWE, expanding significance of clinical value evidence in coverage determinations, and the availability of supplementary data regarding treatment efficacy in routine care environments and heterogeneous patient cohorts.

Among end users, in 2024, the pharmaceutical, biotechnology, and medical device companies segment is expected to account for the largest share of the RWE solutions market. Several variables, including the growing use of RWE to gather real-time post-trial data about medications, monitor drug reactions, and prove the worth of newly created therapies outside of clinical trials, as well as expedited drug trials and extended approvals, are responsible for a substantial share of the segment.

An in-depth analysis of the global RWE solutions market's geographical scenario provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America). It covers the major countries in each region.

In 2024, North America is expected to account for the largest share of the global RWE solutions market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The substantial share of North America can be attributed to various factors, including the rising incidence of chronic illnesses, stricter guidelines for medication approvals, the 21st Century Cures Act, the broad accessibility of electronic datasets, a firmly established healthcare industry, and the growing application of big data in healthcare.

The key players operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), Elevance Health, Inc. (U.S.), ICON plc (Ireland), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Revvity, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Oracle Corporation (U.S.), SAS Institute Inc. (U.S.), Parexel International Corporation (U.S.), and HealthVerity, Inc. (U.S.).

Scope of the Report:

Real-world Evidence Solutions Market Assessment-by Component

  • Datasets
    • Disparate Datasets
  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Genomics Data
  • Other Disparate Datasets
    • Integrated Datasets
  • Consulting Services

Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media.

Real-world Evidence Solutions Market Assessment-by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
    • Oncology
    • Neurology
    • Immunology
    • Cardiovascular Diseases
    • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Other Applications

Note: 1) Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases.

2) Other Applications include regulatory and clinical decision-making.

Real-world Evidence Solutions Market Assessment-by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

Note: Other end users include academic & research institutions, patient advocacy groups, regulators, and health technology assessment agencies.

Real-world Evidence Solutions Market Assessment-by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Switzerland
  • Belgium
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Singapore
  • Australia
  • Rest of Asia-Pacific (RoAPAC)
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation Process
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
  • 2.3. Market Sizing & Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Market Dynamics
      • 4.2.1.1. Drivers
        • 4.2.1.1.1. Rising Focus on Personalized Healthcare
        • 4.2.1.1.2. Delays in Drug Development and the Consequent Increase in Development Costs
        • 4.2.1.1.3. Growing Incidence of Chronic Diseases
        • 4.2.1.1.4. Shift toward Value-based Care
        • 4.2.1.1.5. Rapidly Growing Big Data in the Healthcare Sector
      • 4.2.1.2. Restraints
        • 4.2.1.2.1. Reluctance to Rely on Real-world Studies
      • 4.2.1.3. Opportunities
        • 4.2.1.3.1. Emerging economies
        • 4.2.1.3.2. Rising Focus on End-to-End RWE Services
      • 4.2.1.4. Challenges
        • 4.2.1.4.1. Lack of Standardized Methodologies for Developing RWE
    • 4.2.2. Factors Analysis
  • 4.3. Key Market Trends
    • 4.3.1. The Incorporation of Artificial Intelligence (AI) in the RWE Industry
      • 4.3.1.1. The Adoption of AI Technologies is Growing in the Following Areas:
        • 4.3.1.1.1. Clinical Trials Design
        • 4.3.1.1.2. Modeling and Forecasting Patient Enrichment & Recruitment
        • 4.3.1.1.3. Selecting Investigator Site
        • 4.3.1.1.4. Patient Monitoring & Managing and Medication Adherence & Retention
        • 4.3.1.1.5. AI-enabled Clinical Trial Analytics
        • 4.3.1.1.6. Outsourcing Essential AI Solutions via Strategic Partnerships & Collaborations
        • 4.3.1.1.7. Market Access Using AI Solutions
        • 4.3.1.1.8. Post-market Surveillance Using AI Solutions
    • 4.3.2. Growing Adoption of RWE In Drug Development and Commercialization
    • 4.3.3. Rising Number of Consolidations
    • 4.3.4. Improved Patient Outcomes and Value Creation from Real-World Evidence
  • 4.4. Case Studies For AI-based RWE Solutions
    • 4.4.1. AI-based RWE Solutions for Medical Device Post-market Studies - Huma.AI (U.S.)
    • 4.4.2. AI-enabled RWE Solutions to Support Clinical Decision-making in Drug Research & Development - Owkin, Inc. (France)
    • 4.4.3. AI-integrated RWE Solutions for Market Access - Medaffcon Oy (Finland)
    • 4.4.4. Leveraging Real-world Data Insights Using AI & Machine Learning Algorithms - Aetion, Inc. (U.S.) & Quinten Health (France)
    • 4.4.5. AI-powered RWE Platform to Track Adverse Events - Data2Life (Israel)
    • 4.4.6. AI-powered RWE Solutions to Predict Patients' Health at Critical Care Units - PHASTAR (U.K.)
  • 4.5. Regulatory Analysis
    • 4.5.1. Overview
    • 4.5.2. North America
    • 4.5.3. Europe
    • 4.5.4. Asia-Pacific
    • 4.5.5. Rest of the World
  • 4.6. Pricing Models (EMR/Genomic/Integrated Datasets)
    • 4.6.1. Overview
    • 4.6.2. Pay Per Patient Record (Volume-based Pricing)
    • 4.6.3. Pay Per Usage (Value-based Pricing)
    • 4.6.4. Annual Subscription

5. Real-World Evidence (RWE) Solutions Market Assessment-by Component

  • 5.1. Overview
  • 5.2. Datasets
    • 5.2.1. Disparate Datasets
      • 5.2.1.1. EMR/EHR/Clinical Data
      • 5.2.1.2. Claims & Billing Data
      • 5.2.1.3. Pharmacy Data
      • 5.2.1.4. Product/Disease Registries Data
      • 5.2.1.5. Genomics Data
      • 5.2.1.6. Other Disparate Datasets
    • 5.2.2. Integrated Datasets
  • 5.3. Consulting & Analytics

6. Real-World Evidence Solutions Market Assessment-by Application

  • 6.1. Overview
  • 6.2. Market Access & Reimbursement/Coverage Decisions
  • 6.3. Drug Development & Approvals
    • 6.3.1. Oncology
    • 6.3.2. Neurology
    • 6.3.3. Immunology
    • 6.3.4. Cardiovascular Diseases
    • 6.3.5. Other Therapeutic Areas
  • 6.4. Post-market Surveillance
  • 6.5. Medical Device Development & Approvals
  • 6.6. Other Applications

7. Real-World Evidence (RWE) Solutions Market Assessment-by End User

  • 7.1. Overview
  • 7.2. Pharmaceutical, Biotechnology, and Medical Device Companies
  • 7.3. Healthcare Payers
  • 7.4. Healthcare Providers
  • 7.5. Other End Users

8. Real-world Evidence Solutions Market Assessment-by geography

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. U.K.
    • 8.3.2. Germany
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Switzerland
    • 8.3.7. Belgium
    • 8.3.8. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. South Korea
    • 8.4.5. Australia
    • 8.4.6. Taiwan
    • 8.4.7. Singapore
    • 8.4.8. Rest of Asia-Pacific
  • 8.5. Latin America
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Rest of Latin America
  • 8.6. Middle East & Africa

9. Competitive Landscape

  • 9.1. Introduction
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Benchmarking
  • 9.4. Competitive Dashboard
    • 9.4.1. Industry Leaders
    • 9.4.2. Market Differentiators
    • 9.4.3. Vanguards
    • 9.4.4. Emerging Companies
  • 9.5. Market Share Analysis
    • 9.5.1. IQVIA Holdings Inc. (U.S.)
    • 9.5.2. Icon plc (IRELAND)
    • 9.5.3. Thermo Fisher Scientific Inc. (U.S.)

10. Company Profiles

  • 10.1. IQVIA Holdings, Inc.
  • 10.2. Icon plc
  • 10.3. Thermo Fisher Scientific Inc.
  • 10.4. F. Hoffmann-La Roche Ltd
  • 10.5. Oracle Corporation
  • 10.6. Elevance Health, Inc.
  • 10.7. Clinigen Group Plc
  • 10.8. Cognizant Technology Solutions Corporation
  • 10.9. Revvity, Inc.
  • 10.10. SAS Institute Inc.
  • 10.11. Parexel International Corporation
  • 10.12. Healthverity, Inc.

11. Appendix

  • 11.1. Available Customization
  • 11.2. Related Reports

LIST OF TABLES

  • Table 1 Total Cost Per Study, by Phase and Therapeutic Area (USD Million)
  • Table 2 Sources of Healthcare Data
  • Table 3 Number of People aged 65 years or Over, by Region, 2019 vs. 2050 (Million)
  • Table 4 Strategic Developments of Key Players Related to the Integration of AI into RWE Solutions
  • Table 5 Real-world Evidence Status in Latin America
  • Table 6 Observed Indicative Prices of Real-world Data by Type (USD Per Patient Record)
  • Table 7 Global Real-world Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 8 Global RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 9 Global RWE Datasets Market, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 11 Global RWE Disparate Datasets Market, by Country/Region, 2022-2031 (USD Million)
  • Table 12 Global EMR/EHR/Clinical Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Global Claims and Billing Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Pharmacy Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 15 Global Product/Disease Registries Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 16 Global Genomics Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Other Disparate Datasets Market, by Country/Region, 2022-2031 (USD Million)
  • Table 18 Global RWE Integrated Datasets Market, by Country/Region, 2022-2031 (USD Million)
  • Table 19 Global RWE Consulting & Analytics market, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global Real-world Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 21 Global RWE Solutions Market for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 23 Global RWE Solutions Market for Drug Development & Approvals, by Country/Region, 2022-2031 (USD Million)
  • Table 24 Global RWE Solutions Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 25 Global RWE Solutions Market for Neurology, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Global RWE Solutions Market for Immunology, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Estimated Medical Costs Associated with Cardiovascular Diseases (2020-2030) (USD Billion)
  • Table 28 Global RWE Solutions Market for Cardiovascular Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global RWE Solutions Market for Other Therapeutic Areas, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global RWE Solutions Market for Post-market Surveillance, by Country/Region, 2022-2031 (USD Million)
  • Table 31 Global RWE Solutions Market for Medical Device Development & Approvals, by Country/Region, 2022-2031 (USD Million)
  • Table 32 Global RWE Solutions Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Real-world Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 34 Global RWE Solutions Market for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global RWE Solutions Market for Healthcare Payers, by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global RWE Solutions Market for Healthcare Providers, by Country/Region, 2022-2031 (USD Million)
  • Table 37 Global RWE Solutions Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
  • Table 38 Global RWE Solutions Market, by Country/Region, 2022-2031 (USD Million)
  • Table 39 North America: RWE Solutions Market, by Country, 2022-2031 (USD Million)
  • Table 40 North America: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 41 North America: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 42 North America: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 43 North America: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 44 North America: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 45 North America: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 46 U.S.: RWE Solutions Market, by component, 2022-2031 (USD Million)
  • Table 47 U.S.: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 48 U.S.: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 49 U.S.: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 50 U.S.: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 51 U.S.: RWE Solution, by End User, 2022-2031 (USD Million)
  • Table 52 Canada: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 53 Canada: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 54 Canada: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 55 Canada: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 56 Canada: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 57 Canada: RWE Solution, by End User, 2022-2031 (USD Million)
  • Table 58 EUROPE: RWE solutions Market, by Country/Region, 2022-2031 (USD Million)
  • Table 59 Europe: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 60 Europe: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 61 Europe: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 62 Europe: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 63 Europe: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 64 Europe: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 65 U.K.: Conferences and Workshops on Real-world Evidence Solutions
  • Table 66 U.K.: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 67 U.K.: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 68 U.K.: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 69 U.K.: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 70 U.K.: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 71 U.K.: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 72 Conferences, Symposia, and Workshops in Germany
  • Table 73 Germany: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 74 Germany: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 75 Germany: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 76 Germany: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 77 Germany: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 78 Germany: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 79 France: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 80 France: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 81 France: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 82 France: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 83 France: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 84 France: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 85 Italy: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 86 Italy: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 87 Italy: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 88 Italy: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 89 Italy: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 90 Italy: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 91 Spain: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 92 Spain: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 93 Spain: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 94 Spain: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 95 Spain: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 96 Spain: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 97 Switzerland: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 98 Switzerland: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 99 Switzerland: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 100 Switzerland: RWE solutions Market, by Application, 2022-2031 (USD Million)
  • Table 101 Switzerland: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 102 Switzerland: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 103 Belgium: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 104 Belgium: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 105 Belgium: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 106 Belgium: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 107 Belgium: RWE Solutions Market For Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 108 Belgium: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 109 Rest of Europe: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 110 Rest of Europe: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 111 Rest of Europe: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 112 Rest of Europe: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 113 Rest of Europe: RWE Solutions Market for Drug Development & Approvals, BY Therapeutic Area, 2022-2031 (USD Million)
  • Table 114 Rest of Europe: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 115 Asia-Pacific: RWE Solutions Market, by Country/Region, 2022-2031 (USD Million)
  • Table 116 Asia-Pacific: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 117 Asia-Pacific: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 118 Asia-Pacific: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 119 Asia-Pacific: RWE Solutions Market, By Application, 2022-2031 (USD Million)
  • Table 120 Asia-Pacific: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 121 Asia-Pacific: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 122 Japan: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 123 Japan: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 124 Japan: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 125 Japan: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 126 Japan: RWE Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 127 Japan: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 128 Diversified Real-world Data Sources in China
  • Table 129 China: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 130 China: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 131 China: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 132 China: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 133 China: RWE Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 134 China: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 135 India: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 136 INDIA: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 137 India: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 138 India: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 139 India: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 140 India: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 141 South Korea: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 142 South Korea: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 143 South Korea: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 144 South Korea: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 145 South Korea: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 146 South Korea: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 147 Australia: RWE Solutions Market, By Component, 2022-2031 (USD Million)
  • Table 148 Australia: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 149 Australia: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 150 Australia: RWE Solutions Market, By Application, 2022-2031 (USD Million)
  • Table 151 Australia: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 152 Australia: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 153 RWE Sources in Taiwan
  • Table 154 Taiwan: RWE Solutions Market, By Component, 2022-2031 (USD Million)
  • Table 155 TAIWAN: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 156 Taiwan: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 157 Taiwan: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 158 Taiwan: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 159 Taiwan: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 160 Currently, the Main Sources for Real-world Data (RWD) in Singapore are:
  • Table 161 Singapore: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 162 Singapore: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 163 Singapore: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 164 Singapore: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 165 Singapore: RWE Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 166 Singapore: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 167 Estimated Number of New Cancer Cases from 2022 vs 2025
  • Table 168 rest OF Asia-Pacific: RWE Solutions Market, By Component, 2022-2031 (USD Million)
  • Table 169 Rest of Asia-Pacific: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 170 Rest of Asia-Pacific: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 171 Rest of Asia-Pacific: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 172 Rest of Asia-Pacific: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 173 Rest of Asia-Pacific: RWE Market for Drug Development & Approvals, By End User, 2022-2031 (USD Million)
  • Table 174 Latin America: RWE Solutions Market, by Country/Region, 2022-2031 (USD Million)
  • Table 175 Latin America: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 176 Latin America: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 177 Latin America: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 178 Latin America: RWE Solutions Market, by application, 2022-2031 (USD Million)
  • Table 179 Latin America: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 180 Latin America: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 181 Brazil: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 182 Brazil: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 183 Brazil: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 184 Brazil: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 185 Brazil: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 186 Brazil: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 187 Mexico: RWE Solutions Market Size, by Component, 2022-2031 (USD Million)
  • Table 188 Mexico: RWE Datasets Market Size, by Type, 2022-2031 (USD Million)
  • Table 189 Mexico: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 190 Mexico: RWE Solutions Market, By Application, 2022-2031 (USD Million)
  • Table 191 Mexico: RWE Solutions Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 192 Mexico: RWE Market for Drug Development & Approvals, By End User, 2022-2031 (USD Million)
  • Table 193 Rest of Latin America: RWE Solutions Market, By Component, 2022-2031 (USD Million)
  • Table 194 Rest of Latin America: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 195 Rest of Latin America: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 196 Rest of Latin America: RWE Solutions Market, By Application, 2022-2031 (USD Million)
  • Table 197 Rest of Latin America: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 198 Rest of Latin America: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 199 Middle East & Africa: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 200 Middle East & Africa: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 201 Middle East & Africa: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 202 Middle East & Africa: RWE Solutions Market Size, By Application, 2022-2031 (USD Million)
  • Table 203 Middle East & Africa: RWE Solutions Market size For Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 204 Middle East & Africa: RWE Solutions Market, By End User, 2022-2031 (USD Million)
  • Table 205 Recent Developments, By Company, 2021-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referenced For This Study
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Sizing & Growth Forecast Approach
  • Figure 7 Global RWE Solutions Market, By Component, 2024 Vs. 2031 (USD Million)
  • Figure 8 Global RWE Solutions Market, By Application, 2024 Vs. 2031 (USD Million)
  • Figure 9 Global RWE Solutions Market, By End User, 2024 Vs. 2031 (USD Million)
  • Figure 10 RWE Solutions Market, By Geography 2024 Vs. 2031 (USD Million)
  • Figure 11 Impact Analysis of Market Dynamics
  • Figure 12 Personalized Medicines Approved of Total New Molecular Entities, 2015-2022 (%)
  • Figure 13 Share of Clinical Trials Conducted Between 2017-2021, By Region (%)
  • Figure 14 Global Real-World Solutions Market, By Component, 2024 Vs. 2031 (USD Million)
  • Figure 15 Global Real-World Solutions Market, By Application, 2024 Vs. 2031 (USD Million)
  • Figure 16 Global Real-World Solutions Market, By End User, 2024 Vs. 2031 (USD Million)
  • Figure 17 Global RWE Solutions Market, By Country/Region, 2024 Vs. 2031 (USD Million)
  • Figure 18 North America: RWE Solutions Market Snapshot
  • Figure 19 U.S: Number of Novel Drug Approvals (2016-2023)
  • Figure 20 Europe: RWE Solutions Market Snapshot
  • Figure 21 France: Share of Population Aged 65 and Above, 2017-2023
  • Figure 22 Spain: Pharmaceutical R&D Expenditure, 2019-2022 (USD Million)
  • Figure 23 Switzerland: Pharmaceutical R&D Expenditure, 2019-2022 (USD Million)
  • Figure 24 Pharmaceutical Production in Belgium, 2019-2022 (USD Million)
  • Figure 25 Asia-Pacific: Real-World Evidence Solutions Market Snapshot
  • Figure 26 Latin America: RWE Solutions Market Snapshot
  • Figure 27 Key Growth Strategies Adopted By Leading Players, 2021-2024
  • Figure 28 Real-World Evidence (RWE) Solutions Market: Competitive Benchmarking, by Component
  • Figure 29 Real-World Evidence (RWE) Solutions Market: Competitive Benchmarking, by Region
  • Figure 30 Competitive Dashboard: Real-World Evidence (RWE) Solutions Market
  • Figure 31 Market Share Analysis: Real-World Evidence (RWE) Solutions Industry, 2023
  • Figure 32 IQVIA Holdings, Inc.: Financial Overview (2023)
  • Figure 33 ICON plc: Financial Overview (2023)
  • Figure 34 Thermo Fisher Scientific, Inc.: Financial Snapshot (2023)
  • Figure 35 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2023)
  • Figure 36 Oracle Corporation: Financial Snapshot (2023)
  • Figure 37 Elevance Health, Inc.: Financial Overview (2023)
  • Figure 38 Cognizant Technology Solutions Corporation: Financial Snapshot (2023)
  • Figure 39 Revvity, Inc.: Financial Snapshot (2023)
  • Figure 40 SAS Institute Inc.: Financial Snapshot (2023)